Compact Mass Spectrometer Improves Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compact Mass Spectrometer Improves Analysis


Pharmaceutical Technology
Volume 38, Issue 3, pp. 14

Advion released its latest compact mass spectrometer (CMS), the expression S. The new CMS includes polarity switching during a single analysis to ensure detection of a range of compounds, fast mass scanning (10,000 u/s) for compatibility with UPLC, SFC, and where multiple compounds need to be monitored simultaneously with SIM, as well as higher flow rates of 1-2 mL/min for simpler interfacing with standard chromatographic conditions. The expression S replaces the first generation expression CMS, which will remain available for Advion’s OEM partners. In addition to the hardware advancements, a number of new software features offer additional analysis and data processing options. The software also provides compatibility with DataApex Clarity chromatography software providing seamless integrations with many LC platforms.

Advion

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here